Pharmacyclics (PCYC) Imbruvica CLL Update a Positive for Suitor Abbvie (ABBV) - BMO Capital
Tweet Send to a Friend
BMO Capital analyst Alex Arfaei reiterated his Outperform rating and $68 price target on Abbvie (NYSE: ABBV) as Pharmacyclics' (NASDAQ ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
